GlaxoSmithKline Reports Robust 1Q22 Earnings; Beats Street Estimates

GSK delivered a stellar result for 1Q22, with turnover increasing 32% YOY (32% YOY constant exchange rate or CER) to £9.8 billion (10.5% vs. consensus).